ArticleQuantitative imaging in medicine and surgery2025
Characterization of brain metastases from lung cancer using percentagewise quantification of intratumoral susceptibility signals.
Article in Quantitative imaging in medicine and surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Research progress in imaging detection of brain metastases.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Percentagewise quantification (PQ) of intratumoral susceptibility signals (ITSS) on susceptibility weighted imaging (SWI) serves as an objective and quantitative method capable of differentiating some primary entities of brain metastases (BMs). We aimed to evaluate PQ of ITSS in BMs of different sizes in three main lung cancer subtypes, and explore if it can improve differential diagnosis in the context of lung cancer. Methods: In this retrospective study, 213 patients with synchronous BMs from lung cancer [141 adenocarcinoma (AD), 28 squamous cell carcinoma (SCC), 44 small cell lung cancer (SCLC)], who underwent routine brain contrast-enhanced magnetic resonance imaging (MRI) and contrast-enhanced SWI (CE-SWI), were enrolled. The BMs were delineated on CE-SWI by mutual consent of two radiologists. All voxels within the lesion and voxels presenting values lower than those of the ventricular system were evaluated separately, and then ITSS were percentagewise calculated. The incidence of PQ <1% (no ITSS) and PQ of ITSS in Group 1 (micrometastases, ≤0.125 cm Results: The incidence of no ITSS in Group 1 was higher than that in Groups 2 and 3 in the three subtypes of lung cancer. BMs in Group 2 and Group 3 had higher PQ of ITSS than those in Group 1. In Group 3, PQ of ITSS in AD was higher than that in SCC (P=0.016) and in SCLC (P=0.010), while there was no difference between SCC and SCLC (P=0.921). Diagnostic performance of PQ of ITSS in Group 3 was good [area under the receiver operating characteristic curve (AUC) =0.81; 95% confidence interval (CI): 0.64, 0.98] to discriminate AD from non-AD. At a cut off value of 6.68%, the sensitivity and specificity for differentiation of AD and non-AD were 0.92 and 0.71, respectively. Conclusions: PQ of ITSS can contribute to the non-invasive characterization of BMs from the three subtypes of lung cancer. The larger lesions (middle metastases and macrometastases) of BMs were more likely to have positive ITSS and exhibited higher PQ of ITSS than small ones (micrometastases), and macrometastases of AD and non-AD can be distinguished with high sensitivity and specificity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.